Tang Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Tang Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-126,655	Closed	-$1.52M	–	114
2025 Q3	$1.52M	Hold	126,655	–	–	0.06%	140
2025 Q2	$958K	Hold	126,655	–	–	0.05%	157
2025 Q1	$699K	Hold	126,655	–	–	0.04%	175
2024 Q4	$728K	Hold	126,655	–	–	0.05%	166
2024 Q3	$1.31M	Sell	126,655 -173,345	-58%	-$2.27M	0.09%	103
2024 Q2	$3.89M	Hold	300,000	–	–	0.4%	67
2024 Q1	$5.24M	Hold	300,000	–	–	0.55%	56
2023 Q4	$2.82M	Buy	+300,000	New	+$2.8M	0.26%	80
2023 Q2	–	Sell	-90,000	Closed	-$3.64M	–	103
2023 Q1	$3.64M	Sell	90,000 -110,000	-55%	-$5.25M	0.54%	48
2022 Q4	$9.3M	Buy	200,000 +62,300	+45%	+$2.84M	1.35%	21
2022 Q3	$7.14M	Hold	137,700	–	–	0.88%	36
2022 Q2	$6.51M	Buy	137,700 +37,700	+38%	+$2.05M	0.99%	26
2022 Q1	$7.12M	Buy	+100,000	New	+$6.51M	1.42%	22
2020 Q2	–	Sell	-13,483	Closed	-$693K	–	22
2020 Q1	$693K	Buy	+13,483	New	+$719K	0.1%	21

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tang Capital Management's ENTA Position: Q4 2025 in Review

Tang Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 126,655 shares — an estimated $1.52M sold.

Tang Capital Management first reported a position in ENTA in Q1 2020 and held it in 14 quarters. The position peaked at $9.3M in Q4 2022. 131 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.

Tang Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Tang Capital Management sold 126,655 Enanta Pharmaceuticals shares in Q4 2025, an estimated $1.52M.
Tang Capital Management first reported a position in Enanta Pharmaceuticals in Q1 2020 and held it in 14 quarters.
Tang Capital Management's Enanta Pharmaceuticals position peaked at $9.3M in Q4 2022.
131 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.